- Price
- $4.40
- Day
- +5.52%
- Mkt Cap
- $159.73M
- 52W Range
- $2.90 – $10.08
- Volume
- 748.7K
- Beta
- 0.41
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Immuneering Corporation targets first-line pancreatic cancer with atebimetinib, showing promising Phase 2a results versus standard-of-care regimens. IMRX's pivotal Phase 3 trial in first-line PDAC is recruiting, with first patient dosing expected mid-2026 and cash runway projected into 2029. Atebimetinib demonstrated median overall survival of 17.3 months, outperforming historical controls and comparing favorably to competitors' data.
Read full article
- Atebimetinib showed broad antitumor activity across KRAS-, NRAS-, and BRAF-mutant models, including colorectal, lung, and melanoma, by resisting the RAF-mediated bypass signaling that has constrained other MEK inhibitors -
Read full article
NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, previously announced on June 15, 2026, that Andrew Gengos was named Chief Financial Officer of the Company, effective as of July 16, 2026 (the “Start Date”). In connection with the commencement of Mr.
Read full article
Immuneering (IMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read full article